Elecoglipron
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca · Phase 1 · Recruiting · Enrollment 152
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cohort 1-Treatment Sequence A | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 1 - Treatment Sequence B | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence C | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence D | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence E | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence F | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence G | Healthy Participants | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence H | Healthy Participants | n/r | n/r | n/r | n/r |